AVITA Medical, Inc. (ASX:AVH)

Market Cap	175.06M -55.1%
Revenue (ttm)	109.46M +20.6%
Net Income	-73.41M
EPS	-2.74
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	65,227
Average Volume	492,923
Open	1.130
Previous Close	1.115
Day's Range	1.120 - 1.140
52-Week Range	1.000 - 3.380
Beta	1.80
RSI	45.96
Earnings Date	Feb 12, 2026

About AVITA Medical

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting devi...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2020
• Employees: 260
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: AVH

Financial Performance

In 2024, AVITA Medical's revenue was $64.25 million, an increase of 28.14% compared to the previous year's $50.14 million. Losses were -$61.85 million, 74.8% more than in 2023.

Financial numbers in USD